Discovery of a potent and selective agonist of the prostaglandin EP4 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1129-1132

  Billot, Xavier ^a,b   Chateauneuf, Anne ^a   Chauret, Nathalie ^a   Denis, Danielle ^a   Greig, Gillian ^a   Mathieu, Marie Claude ^a   Metters, Kathleen M ^a   Slipetz, Deborah M ^a   Young, Robert N ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANONE; HYDROXYCYCLOPENTANONE; LACTAM; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP4 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 0037463795     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00042-8     Document Type: Article

References (21)

1. Coleman R.A., Smith W.L., Narumiya S. Pharmacol. Rev. 46:1994;205.
2. Narumiya S., Sugimoto Y., Ushikubi F. Physiol. Rev. 79:1999;1193.
3. Pilbeam, C. C.; Harrison, J. R.; Raisz, L. G. In Principles of Bone Biology; Bilekizian, J. P., Raisz, J. P., Rodan, G. A., Eds, Academic: San Diego, 1996; p. 715.
4. (a) Rodan G.A. J. Cell. Biochem. (Suppl. 15):1991;160
5. (b) Ueno K., Haba T., Woodbury D., Price P., Anderson R., Jee W.S.S. Bone. 6:1985;79
6. (c) Jee W.S.S., Ke H.Z., Li X.J. Bone Mineral. 15:1991;33
7. (d) Norrdin, R. W.; Jee, W. S. S.; High, W. B. Prostaglandins Leukot. Essent. Fatty Acids 1990, 41, 139.
8. Miyaura C., Inada M., Suzawa T., Sugimoto Y., Ushikubi F., Ichikawa A., Narumiya S., Suda T. J. Biol. Chem. 275:2000;19819.
9. Machwate M., Harada S., Leu T., Seedor G., Labelle M., Gallant M., Hutchins S., Lachance N., Sawyer N., Slipetz D., Metters K.M., Rodan S.B., Young R., Rodan G.A. Mol. Pharmacol. 60:2001;36.
10. 4 receptor have shown significant bone formation in rats which further supports this hypothesis. See: Proc. Natl. Acad. Sci. U.S.A. 99:2002;4580.
11. Abramovitz M., Adam M., Boie Y., Carriere M.-C., Denis D., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., Metters K.M. Biochem. Biophys. Acta. 1483:2000;285.
12. Smith R.L., Lee T., Gould N.P., Cragoe E.J. Jr., Oien H.G., Kuehl F.A. Jr. J. Med. Chem. 20:1977;1292.
13. Maruyama T., Asada M., Shiraishi T., Yoshida H., Maryama T., Ohuchida S., Nakai H., Kondo K., Toda M. Bioorg. Med. Chem. 10:2002;1743.
14. Hamberg M., Samuelsson B. J. Biol. Chem. 246:1971;6713.
15. Hansen H.S. Prostaglandins. 12:1976;647.
16. Yoda H., Oguchi T., Takabe K. Tetrahedron: Asymmetry. 7:1996;2113.
17. Slipetz D., Buchanan S., Mackereth C., Brewer N., Pellow V., Hao C., Adam M., Abramovitz M., Metters K.M. Biochem. Pharmacol. 62:2001;997.
18. Nicoll-Griffith D.A., Falgueyret J.-P., Silva J.M., Morin P.E., Trimble L., Chan C.-C., Clas S., Leger S., Wang Z., Yergey J.A., Riendeau D. Drug Metab. Disp. 27:1999;403.
19. 4 receptor agonists for treatment of osteoporosis have recently been published. See: (a) Cameron, K. O.; Lefker, B. A. WO 0242268 A2. (b) Cameron, K. O.; Ke, H.; Lefker, B. A.; Thompson, D. D. WO 0146140 A1. (c) Maruyama, T.; Kobayashi, K.; Maruyama, T. WO 0224647 A1.
20. 4 receptor agonists for treatment of osteoporosis have recently been published. See: (a) Cameron, K. O.; Lefker, B. A. WO 0242268 A2. (b) Cameron, K. O.; Ke, H.; Lefker, B. A.; Thompson, D. D. WO 0146140 A1. (c) Maruyama, T.; Kobayashi, K.; Maruyama, T. WO 0224647 A1.
21. 4 receptor agonists for treatment of osteoporosis have recently been published. See: (a) Cameron, K. O.; Lefker, B. A. WO 0242268 A2. (b) Cameron, K. O.; Ke, H.; Lefker, B. A.; Thompson, D. D. WO 0146140 A1. (c) Maruyama, T.; Kobayashi, K.; Maruyama, T. WO 0224647 A1.